Quick Answer
Nuo Therapeutics, Inc. reported Cash and Equivalents of $548.9 thousand for fiscal year 2025.
Nuo Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $548.9K | +93.5% |
| 2024 | $283.7K | -69.4% |
| 2023 | $928.7K | -54.7% |
| 2022 | $2.05M | +45.0% |
| 2021 | $1.41M | +853.0% |
| 2021 | $148.4K | -2.1% |
| 2021 | $151.6K | -3.6% |
| 2021 | $157.3K | -2.6% |
| 2020 | $161.4K | — |
| 2020 | $0.00 | -100.0% |
| 2020 | $13.00 | -99.9% |
| 2020 | $11.2K | -44.7% |
| 2019 | $20.3K | -96.8% |
| 2018 | $636.9K | -8.2% |
| 2017 | $693.5K | -73.5% |
| 2016 | $2.62M | -74.7% |
| 2016 | $10.36M | +1023.1% |
| 2015 | $922.3K | -94.2% |
| 2014 | $15.95M | +385.2% |
| 2013 | $3.29M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $514.8K | -24.7% | +62.7% |
| June 30, 2025 | $316.4K | -33.1% | +468.4% |
| March 31, 2025 | $55.7K | -84.8% | -80.4% |
| December 31, 2024 | $283.7K | -69.4% | -58.5% |
| September 30, 2024 | $683.8K | +17.4% | +44.6% |
| June 30, 2024 | $473.0K | +37.4% | +29.2% |
| March 31, 2024 | $366.2K | -70.7% | -60.6% |
| December 31, 2023 | $928.7K | -54.7% | +59.4% |
- Nuo Therapeutics, Inc. showed an increase of +93.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2013–2025 period, Nuo Therapeutics, Inc.’s cash and equivalents has declined by 83.3% (from $3.29 million to $548.9 thousand).
- The most recent figure is from Nuo Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: